[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628967":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":130,"collaborators":132,"id":147,"slug":148,"hasResults":149,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":149,"sex":155,"minAge":156,"maxAge":26,"enrollmentInfo":157,"targetDuration":26,"studyType":160,"phases":161,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":168,"whyStopped":26,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},{"fullName":5,"class":6},"Menzies School of Health Research","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"High-dose Short-course Primaquine (PQ7)","ACTIVE_COMPARATOR","Participants in this arm will receive a high-dose, short-course primaquine regimen (PQ7), consisting of a total dose of 7 mg\u002Fkg administered as 1 mg\u002Fkg once daily in the morning for 7 days (Day 0-6). A matching placebo will be given in the evening on the first three days (Day 0-2).",[13,14],"Drug: High dose ultra short Primaquine","Other: Placebo",{"label":16,"type":17,"description":18,"interventionNames":19},"High dose ultra- short course Primaquine (PQ 3.5)","EXPERIMENTAL","Participants in this arm will receive a high-dose, ultra-short primaquine regimen (PQ3.5), consisting of a total dose of 7 mg\u002Fkg administered as 1 mg\u002Fkg twice daily for 3.5 days (Day 0-2 morning and evening doses, and Day 3 morning dose). A matching placebo will be given as the morning dose on Days 4-6.",[13,14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","High dose ultra short Primaquine","High-dose, ultra-short primaquine (PQ3.5): 7mg\u002Fkg total dose given as 1mg\u002Fkg twice daily over 3.5 days (day 0, 1 and 2 morning and evening doses, and day 3 morning dose) followed by placebo as morning doses on day 4, 5 and 6.",[16,9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Matching placebo administered according to the arm schedule. Morning dose on Days 4-6 for PQ3.5 arm and Evening dose on the first 3 days for PQ 7 arm).",[16,9],[32],{"name":33,"affiliation":5,"role":34},"Kamala Thriemer, Professor","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+61889468644","Kamala.Ley-Thriemer@menzies.edu.au",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},"Hellen Mnjala, MSc","+61889468675","hellen.mnjala@menzies.edu.au",[45,62,76,94,112],{"facility":46,"status":26,"city":47,"state":47,"zip":26,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Arba Minch University","Arba Minch","Ethiopia","ET",{"type":51,"coordinates":52},"Point",[53,54],37.55,6.03333,{"lat":54,"lon":53},[57,61],{"name":58,"role":37,"phone":59,"phoneExt":26,"email":60},"Dr Tamiru Degaga","+252911704767","drtamshib1@gmail.com",{"name":58,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":63,"status":26,"city":64,"state":64,"zip":26,"country":48,"countryCode":49,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Jimma University","Jimma",{"type":51,"coordinates":66},[67,68],36.83441,7.67344,{"lat":68,"lon":67},[71,75],{"name":72,"role":37,"phone":73,"phoneExt":26,"email":74},"Dr Daniel Yilma","+251471111458","danielyilmab@gmail.com",{"name":72,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":77,"status":26,"city":78,"state":79,"zip":26,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Universitas Sumatera","Bandar Lampung","Lampung","Indonesia","ID",{"type":51,"coordinates":83},[84,85],105.26111,-5.42917,{"lat":85,"lon":84},[88,92],{"name":89,"role":37,"phone":90,"phoneExt":26,"email":91},"Dr Ayodhia Pitaloka Pasaribu, Professor","+628126024392","ayodhia@usu.ac.id",{"name":93,"role":34,"phone":26,"phoneExt":26,"email":26},"Dr Ayodhia Pitaloka Pasaribu",{"facility":95,"status":26,"city":96,"state":97,"zip":26,"country":98,"countryCode":99,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Aga Khan University, Karachi","Karachi","Thatta","Pakistan","PK",{"type":51,"coordinates":101},[102,103],67.0104,24.8608,{"lat":103,"lon":102},[106,110],{"name":107,"role":37,"phone":108,"phoneExt":26,"email":109},"Dr Asim Beg, Professor","+923002028490","masim.beg@aku.edu",{"name":111,"role":34,"phone":26,"phoneExt":26,"email":26},"Dr Asim Beg",{"facility":113,"status":26,"city":114,"state":115,"zip":26,"country":116,"countryCode":117,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Papua New Guinea Institute of Medical Research","Port Moresby","Magang","Papua New Guinea","PG",{"type":51,"coordinates":119},[120,121],147.15089,-9.47723,{"lat":121,"lon":120},[124,128],{"name":125,"role":37,"phone":126,"phoneExt":26,"email":127},"DR Moses Laman","+6754340208","moses.laman@pngimr.org.pg",{"name":129,"role":34,"phone":26,"phoneExt":26,"email":26},"Dr Moses Laman",{"type":131,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[133,135,137,139,140,141,143,145],{"name":134,"class":6},"Curtin University",{"name":136,"class":6},"University of Melbourne",{"name":113,"class":138},"OTHER_GOV",{"name":46,"class":6},{"name":63,"class":6},{"name":142,"class":6},"Universitas Sumatera Utara",{"name":144,"class":6},"Aga Khan University",{"name":146,"class":138},"PathWest Laboratory Medicine WA","100628967","phase-3-an-ultra-short-course-of-primaquine-for-the-radical-cure-of-vivax-malaria-100628967",false,"NCT07468526","An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria","An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria (PRIMUS)","PRIMUS","Inclusion Criteria:\n\n* P. vivax peripheral parasitaemia as determined by microscopy\n* G6PD normal status (G6PD activity ≥70% of the site specific adjusted male median as determined by the Standard G6PD (SD Bioline, ROK))\n* Fever (temperature ≥37.5°C) or history of fever in the preceding 48 hours,\n* Age ≥5 years\n* Bodyweight ≥14kg\n* Living in the study area and willing to be followed-up for six months\n\nExclusion Criteria:\n\n* Signs or symptoms of severe malaria,\n* Anaemia (defined as Hb \\\u003C8g\u002Fdl) and measured by the Standard G6PD\n* Pregnant or lactating\n* Blood transfusion within the preceding four months\n* Regular or recent use (last month) of tafenoquine, primaquine or dapsone\n* Known hypersensitivity to any of the study drugs","ALL","5 Years",{"count":158,"type":159},1019,"ESTIMATED","INTERVENTIONAL",[162],"PHASE3","Current treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes, but this needs to be balanced against increased risk of side effects. Recent data from a trial in children in Papua New Guinea (PNG) suggests a shortened treatment of 3 days is safe and effective. Our multicentre trial will assess the safety and efficacy of an ultra-short primaquine course. This trial is expected to directly influence global treatment policies.",[165],"Malaria",[167,153],"An ultra-short course of primaquine for the radical cure of vivax malaria","NOT_YET_RECRUITING","2026-03-09",{"date":171,"type":172},"2026-03-12","ACTUAL",{"date":174,"type":159},"2026-06-01",{"date":176,"type":159},"2028-04-01",{"name":5,"class":6},5]